iBio stockholders approve share authorization boost and incentive plan change
At its October 14, 2026 annual meeting, iBio investors backed raising authorized common stock and amending the equity incentive plan's evergreen formula.
iBio, Inc. held its 2026 Annual Meeting of Stockholders on October 14, 2026, according to an 8-K filed with the Securities and Exchange Commission. The meeting drew 48,244,264 shares represented in person or by proxy, enough to meet quorum requirements.1
Stockholders voted on six proposals. They approved amending the company's Certificate of Incorporation to raise the authorized common stock count roughly from 275 million to 500 million shares.1 The company filed the corresponding Certificate of Amendment with Delaware's Secretary of State on October 16, 2026, and it took effect immediately upon filing.1
Shareholders also approved an amendment to the company's 2023 Omnibus Incentive Plan. Under the change, the plan's "evergreen" share reserve will grow automatically each January 1 from 2027 through 2029 by 5% of outstanding common stock as of the prior December 31, plus 3% of shares issuable from outstanding pre-funded warrants, and then by 5% of outstanding common stock alone each January 1 from 2030 through 2033, unless the board acts beforehand to set a smaller increase for a given year.1
In other votes, stockholders elected William Clark and Gary Sender as Class III directors for three-year terms, ratified Grassi & Co., CPAs, P.C. as the company's independent registered public accounting firm for the fiscal year ending June 30, 20271, approved an advisory say-on-pay resolution, and approved a proposal to allow adjournment of the meeting if needed, though that adjournment ultimately proved unnecessary since the other two key proposals had already secured sufficient votes.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.